Navigation Links
Laresse Dermal Filler Research Presented at Anti-Aging World,Congress

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed, Inc. announced today that a review of the company's research on novel, synthetic dermal fillers is being presented at the Anti-Aging Medical World Congress (AAMWC) in Monte Carlo March 22-24, 2007.

In 2006, FzioMed launched Laresse Dermal Filler, the first ultra-smooth, non-permanent, synthetic filler created from the company's patented polymer science. Laresse represents a completely new class of filler for the correction of wrinkles and lines caused by sun exposure, aging and other factors.

After extensive characterization of cross-linked hyaluronic acid (HA) fillers, FzioMed designed Laresse from biocompatible polymers to have key gel properties that offer significant advantages over common fillers being used today. For example, Laresse is stable without chemical cross-linking, completely free of both bacterial and animal by-products, and smoother and easier to inject than HA fillers.

Richard Berg, Ph.D., FzioMed's Chief Scientific Officer, will present "Novel Synthetic Dermal Fillers" at AAMWC on March 24th. His talk will describe the rheological properties of commercialized cross-linked HA fillers and includes data demonstrating the broader versatility and advantages of FzioMed's polymer technology for formulating a family of improved dermal fillers, including Laresse.

"This presentation highlights FzioMed's approach of applying science to the rapidly evolving field of soft tissue augmentation," said John Krelle, FzioMed President & Chief Executive Officer.

About Laresse

Laresse Dermal Filler is an ultra-smooth, non-permanent, non-HA gel composed of pure, absorbable medical polymers. Laresse is the first non-permanent filler without many of the drawbacks of HA and collagen fillers. No other filler offers the same features as Laresse: non-permanent wrinkle correction, non-animal and non-bacterial compone nts, easy injection through a very fine needle, and ultra-smooth texture and feel. Laresse is currently available only in the EU.

About FzioMed

FzioMed is a privately held medical company developing and commercializing absorbable biomaterials based on the company's patented science. FzioMed's polymer technology has uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the U.S., Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse dermal filler. FzioMed products are for investigational use only in the U.S.

FzioMed(R), Oxiplex(R) and Laresse(R) are trademarks of FzioMed, Inc.

Contact

FzioMed UK
Amanda Cameron, +44-800-902-0720
or
FzioMed USA
Jan W. Haynes, +805-546-0610


'"/>




Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. NIEHS Researchers Identify Enzyme Critical in DNA Replication
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. Researchers Discover Method for Identifying How Cancer Evades the Immune System
7. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
8. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
9. President Bush Ignores Americas Plea for Support of Stem Cell Research
10. Researchers Discover Gene For Rare Skin Disorder
11. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
Breaking Medicine News(10 mins):